Search Videos by Topic or Participant
Browse by Series:

Role of the Endocrinologist in RAI-Refractory Thyroid Cancer

Panelists: Marcia S. Brose, MD, PhD, UPenn; Naifa L. Busaidy, MD, MD Anderson;Gary L. Clayman, DMD, MD, MD Anderson; Ezra Cohen, MD, UCSD;
Published: Tuesday, Aug 26, 2014
For High-Definition, Click
Endocrinologists maintain an important role in the treatment of patients with thyroid cancer, from diagnosis through systemic therapy. As a result, it is important for endocrinologists to understand the implications of radioactive iodine (RAI)-refractory disease, notes Naifa L. Busaidy, MD. Additionally, to foster future collaboration, early referrals should be made to medical oncologists, to ease the transition if systemic therapy is required.

For patients with RAI-refractory thyroid cancer, treatment should be carried out in a multidisciplinary fashion that includes input from the endocrinologist, surgeon, and medical oncologists, states Busaidy. This relationship should continue even as systemic therapy is administered, since endocrinologists play an important role in monitoring thyroid stimulating hormone (TSH) suppression, adds Manisha H. Shah, MD. TSH suppression, hypocalcemia, and other side effects can be common with the administration of TKIs, notes Marcia S. Brose, MD, PhD.

The most common side effect seen with the TKIs sorafenib and cabozantinib is hand-foot syndrome, notes Francis P. Worden, MD. Additionally, diarrhea can be a concern, particularly if it results in an electrolyte imbalance. QT prolongation should be monitored with vandetanib, although the occurrence of this side effect is rare, Worden states.

To monitor for these adverse events, patients should be seen every 2 weeks following the initiation of therapy. If the disease is stable, short treatment breaks along with active surveillance can be utilized to address lingering adverse events, such as fatigue, Worden notes.
Slider Left
Slider Right
For High-Definition, Click
Endocrinologists maintain an important role in the treatment of patients with thyroid cancer, from diagnosis through systemic therapy. As a result, it is important for endocrinologists to understand the implications of radioactive iodine (RAI)-refractory disease, notes Naifa L. Busaidy, MD. Additionally, to foster future collaboration, early referrals should be made to medical oncologists, to ease the transition if systemic therapy is required.

For patients with RAI-refractory thyroid cancer, treatment should be carried out in a multidisciplinary fashion that includes input from the endocrinologist, surgeon, and medical oncologists, states Busaidy. This relationship should continue even as systemic therapy is administered, since endocrinologists play an important role in monitoring thyroid stimulating hormone (TSH) suppression, adds Manisha H. Shah, MD. TSH suppression, hypocalcemia, and other side effects can be common with the administration of TKIs, notes Marcia S. Brose, MD, PhD.

The most common side effect seen with the TKIs sorafenib and cabozantinib is hand-foot syndrome, notes Francis P. Worden, MD. Additionally, diarrhea can be a concern, particularly if it results in an electrolyte imbalance. QT prolongation should be monitored with vandetanib, although the occurrence of this side effect is rare, Worden states.

To monitor for these adverse events, patients should be seen every 2 weeks following the initiation of therapy. If the disease is stable, short treatment breaks along with active surveillance can be utilized to address lingering adverse events, such as fatigue, Worden notes.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x